SAS and Thread have introduced a new offering to support biopharma companies with data preparation. Credit: metamorworks/Shutterstock.com.

Artificial intelligence (AI) and analytics leader SAS, and Thread, have introduced a new offering together to support biopharma companies with data preparation, assessment, and submission.

With the new offering, the companies will be able to modernise their clinical research using a simple and cost-effective method.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It integrates the comprehensive, cloud-native analytics of SAS with the decentralised clinical trial (DCT) and electronic clinical outcome assessment (eCOA) platform of Thread.

SAS’ Statistical Computing Environment (SCE) solution will initially be integrated with Thread’s technology platform, providing access to data, analysis, and visualisation for shared customers.

This integration will allow SAS and Thread to build on their initial partnership and expand into DCT-specific analytics by combining the data elements, captured by Thread, with SAS AI, visualisation, and machine learning.

See Also:

Featuring a consolidated analytics environment, the regulatory compliance-enabled solution gathers data from various sources, including participant and clinician-reported data provided by Thread.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, Thread’s data can be surfaced within customer-specific SAS analytical environments for larger pharmaceutical companies.

Thread co-founder and CEO John Reites said: “To meet the evolving needs of clinical trial participants in the age of digital health, research organisations are transforming the way they discover, develop, manufacture, and commercialise new therapies.

“We are excited to partner with SAS to provide this unique solution to biopharma customers who want to collect data via next-generation research designs.”

In March this year, Thread, along with United BioSource (UBC), launched the next-generation, post-approval research model, SitePlus.